TABLE 3.
Concentrations of MMP-2 and MMP-9 in CSF samples from infant rats treated with MMP and/or TACE inhibitors during the acute phase of PM
| Parameter | Mean value ± SD (no. of animals) |
||
|---|---|---|---|
| Vehicle | Ro 32-3555 | Ro 32-7315 | |
| MMP-9 concn (ng/ml) at: | |||
| 18 hpi | 1,468 ± 2,689 (32) | 778 ± 1,168 (20) | 262 ± 280 (20) |
| 27 hpi | 377 ± 334 (20) | 200 ± 112 (21) | 235 ± 155 (4) |
| 42 hpi | 238 ± 225 (7) | 352 ± 420 (12) | 39.2 ± 13 (4) |
| MMP-9/MMP-2 ratio at: | |||
| 18 hpi | 2.80 ± 1.70 (32) | 2.19 ± 1.41 (20) | 2.98 ± 1.96 (20) |
| 27 hpi | 1.07 ± 0.47 (25) | 0.84 ± 0.41 (21) | 1.06 ± 0.49 (7) |
| 42 hpi | 0.54 ± 0.19 (7) | 0.55 ± 0.33 (12) | 033 ± 0.08 (4) |
| Collagen concn (μg/ml) at: | |||
| 18 hpi | 40.9 ± 12.5 (27) | 33.1 ± 5.0 (12)a | 44.1 ± 8.7 (22) |
| 27 hpi | 60.1 ± 17.3 (7) | 58.7 ± 17.3 (5) | n = 0 |
a
Significantly different (P < 0.05) from the value for vehicle-treated animals.